Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells

Oncology

Volumn 74, Issue 3-4, 2008, Pages 198-206

  Bu, Youquan ^a   Yang, Zhengmei ^a   Li, Quanhai ^b   Song, Fangzhou ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Esophageal cancer; Polo like kinase 1; RNA silencing

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; POLO LIKE KINASE 1; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINESIS; ESOPHAGUS CANCER; GENE SILENCING; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SISTER CHROMATID;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYTOKINESIS; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; GENE THERAPY; HUMANS; MITOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SISTER CHROMATID EXCHANGE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 49549100682     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151367     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Donaldson MM, Tavares AA, Hagan IM, Nigg EA, Glover DM: The mitotic roles of polo-like kinase. J Cell Sci 2001;114:2357-2358.
3. Glover DM, Hagan IM, Tavares AA: Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998;12:3777-3787.
4. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA: Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994;107:1509-1517.
5. Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-330.
6. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-291.
7. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y: Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999;15:687-692.
8. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK: Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997;234:397-405.
9. LinksRizki A, Mott JD, Bissell MJ: Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res 2007;67:11106-11110.
10. Liu X, Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789-5794.
11. Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K: Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94:1863-1877.
12. Reagan-Shaw S, Ahmad N: Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005;19:611-613.
13. Liu X, Lei M, Erikson RL: Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26:2093-2108.
14. Toyoshima-Morimoto F, Taniguchi E, Nishida E: Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3:341-348.
15. Rodier F, Campisi J, Bhaumik D: Two faces of p53: aging and tumor suppression. Nucleic Acids Res 2007;35:7475-7484.
16. Moshe Y, Boulaire J, Pagano M, Hershko A: Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci USA 2004;101:7937-7942.
17. Hansen DV, Loktev AV, Ban KH, Jackson PK: Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFβTrCP-dependent destruction of the APC inhibitor Emi1. Mol Biol Cell 2004;15:5623-5634.
18. Liu X, Erikson RL: Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA 2002;99:8672-8676.
19. Sato F, Abraham JM, Yin J, Kan T, Ito T, Mori Y, Hamilton JP, Jin Z, Cheng Y, Paun B, Berki AT, Wang S, Shimada Y, Meltzer SJ: Polo-like kinase and survivin are esophageal tumor-specific promoters. Biochem Biophys Res Commun 2006;342:465-471.
20. Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G, Marshall LA: The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 2000; 12:405-411.
21. McGowan CH, Russell P: Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993;12:75-85.
22. Wells NJ, Watanabe N, Tokusumi T, Jiang W, Verdecia MA, Hunter T: The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression. J Cell Sci 1999;112:3361-3371.
23. Liu X, Zhou T, Kuriyama R, Erikson RL: Molecular interactions of polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1. J Cell Sci 2004;117:3233-3246.
24. Zhou T, Aumais JP, Liu X, Yu-Lee LY, Erikson RL: A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 2003;5:127-138.
25. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A: Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004;279:25549-25561.
26. Koida N, Ozaki T, Yamamoto H, Ono S, Koda T, Ando K, Okoshi R, Kamijo T, Omura K, Nakagawara A: Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 2008;283:8555-8563.